FDA doesn't see increased risk of stroke for seniors who received Pfizer's omicron booster

Key Facts

• The FDA launched an extensive review of federal data after investigators at the Centers for Disease Control and Prevention detected a possible risk of stroke for seniors who received Pfizer’s booster.
• CNBC HEALTH & SCIENCE Read CNBC’s latest global health coverage: FDA doesn’t see increased risk of stroke for seniors who received Pfizer’s omicron booster Omicron booster shots provide some protection against mild illness from Covid XBB subvariants, CDC says Abortion pill manufacturer GenBioPro sues West Virginia, argues FDA rules pre-empt state ban Bill Gates says no country ‘gets an A’ for its Covid pandemic response—including the U.S. FDA proposes new lead limits for baby food to reduce potential risks to children’s health The FDA’s power to approve drugs faces sweeping challenge in lawsuit seeking to pull abortion pill from U.S. market FDA says Covid vaccines will probably get an annual update but most people will only need one shot FTC asks judge to hold ‘pharma bro’ Martin Shkreli in contempt of court for forming new drug firm * Moderna says RSV vaccine is 84% effective at preventing disease in older adults The FDA reviewed CMS data from 4.25 million seniors who received Pfizer’s omicron booster and did not identify any increased stroke risk.
• “We contacted a number of our international regulatory agencies, and various countries in Europe as well as Israel have indicated no increased risk of stroke on their surveillance systems,” Forshee told the FDA committee.
• However, the investigators ran small analysis that indicated seniors who received both the Pfizer omicron booster and a high-dose or adjuvanted flu vaccine on the same day may have a higher risk of stroke, though the data is preliminary.

Click To Read Full Article